darusentan
Sign in to saveAlso known as HMR-4005, LU-135252
Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.
Research
205 papers- Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension.Therapeutic advances in cardiovascular disease · 2010
- Darusentan: a new perspective for treatment of resistant hypertension?Expert opinion on investigational drugs · 2008
- Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis.Cardiovascular research · 2024
- Darusentan (Abbott Laboratories).IDrugs : the investigational drugs journal · 2001
- Darusentan is a potent inhibitor of endothelin signaling and function in both large and small arteries.Canadian journal of physiology and pharmacology · 2010
via PubMed
Wikidata facts
- Mass
- 410.147786
Show 5 more facts
- chemical formula
- C₂₂H₂₂N₂O₆
- isomeric SMILES
- COC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)OC
- canonical SMILES
- COC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)OC
- subject has role
- Endothelin receptor antagonist
- Commons category
- Darusentan
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.
In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.
Excerpted from Wikipedia’s “darusentan” article, available under the CC BY-SA 4.0 licence.